It does not receive public funding
Editor in chief:

Facebook Twitter Youtube Instagram LinkedIn

Do you want to access to this and other private contents?
Log in if you are a subscriber or click here to request service

Palforzia of Aimmune is the first treatment for peanut allergy in the EU

Approved the use of the biological drug, developed by Nestlé health science company

The European Commission has approved the use of Palforzia (defatted powder of Arachis hypogaea L.) for the treatment of peanut allergy in the European Union (EU). Developed by Aimmune Therapeutics, Inc., a Nestlé Health Science Company, Palforzia is an oral immunotherapy indicated in patients aged 4 to 17 years, who have a confirmed diagnosis of peanut allergy. Palforzia may be continued in patients...

hef - 16007

EFA News - European Food Agency